Comparative Pharmacology
Head-to-head clinical analysis: NARDIL versus TRANYLCYPROMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NARDIL versus TRANYLCYPROMINE SULFATE.
NARDIL vs TRANYLCYPROMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible, non-selective monoamine oxidase inhibitor (MAOI) that increases synaptic concentrations of monoamines (norepinephrine, serotonin, dopamine) by inhibiting their oxidative deamination.
Irreversible inhibitor of monoamine oxidase (MAO-A and MAO-B), thereby increasing synaptic concentrations of monoamines (e.g., serotonin, norepinephrine, dopamine).
Initial: 15 mg orally three times daily; increase gradually to 45-60 mg/day in divided doses; maximum 90 mg/day.
Adults: 10 mg orally twice daily, increasing if necessary after 2 weeks to 30 mg/day in divided doses; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 11–13 hours; due to irreversible MAO inhibition, clinical effects persist for 1–2 weeks after discontinuation.
The terminal elimination half-life is approximately 2 hours (range 1.5–3 hours). However, MAO inhibition persists for 7–14 days after discontinuation due to irreversible enzyme binding.
Renal: 70–80% as metabolites and unchanged drug; biliary/fecal: 20–30%.
Renal excretion of metabolites (primarily as conjugates) accounts for approximately 90% of elimination, with less than 1% excreted unchanged in urine. Fecal excretion is minimal.
Category C
Category C
MAOI Antidepressant
MAOI Antidepressant